Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Tudor–Eliade Ciuleanu, Adam Płużański, Shun Lü, Hossein Borghaei et al.
Citations
22 citations
Journal
Journal of Thoracic Oncology
Topics
Cancer Immunotherapy and Biomarkers
Field-Weighted Citation Impact (FWCI)
6.22
article
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Tudor–Eliade Ciuleanu, Adam Płużański, Shun Lü, Hossein Borghaei, Bogdan Żurawski, Diederik J. Grootendorst, Julie R. Brahmer, Manuel Cobo, Michael Schenker, Vipul Devas, Kenneth J. O’Byrne, Marina Tschaika, Luis Paz‐Ares, David P. Carbone, Martin Reck, Solange Peters, Reyes Bernabé, Makoto Nishio, Suresh S. Ramalingam, Thomas John, Jong-Seok Lee, Takekazu Aoyama
article en
22 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Thoracic OncologyVol. 20(1)
Institutions
Universidad Complutense de Madrid (ES), Fox Chase Cancer Center (US), Translational Research Institute (AU), Emory University (US), Queensland University of Technology (AU), Austin Hospital (AU), Princess Alexandra Hospital (AU), Centre Hospitalier Universitaire Vaudois (CH), Shanghai Chest Hospital (CN), Seoul National University Bundang Hospital (KR), University of Medicine and Pharmacy of Craiova (RO), Bristol-Myers Squibb (United States) (US), Institute of Oncology Prof. Dr. Ion Chiricuta (RO), Hospital Universitario 12 De Octubre (ES), Hôpital Orthopédique de la Suisse Romande (CH), German Center for Lung Research (DE), Instituto de Biomedicina de Sevilla (ES), Bristol-Myers Squibb (Sweden) (SE), LungenClinic Grosshansdorf (DE), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Sidney Kimmel Comprehensive Cancer Center (US), Instituto de Investigación Biomédica de Málaga (ES), Japanese Foundation For Cancer Research (JP), The Ohio State University (US), University of Lausanne (CH)